References
Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410–6.
Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623–7.
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–7.
Shields CL, Say EAT, Mashayekhi A, Garg SJ, Dunn JP, Shields JA. Assessment of CTLA-4 deficiency-related autoimmune choroidopathy response to abatacept. JAMA Ophthalmol. 2016;134(7):844–6.
Lee S, Moon JS, Lee C-R, Kim H-E, Baek S-M, Hwang S, et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol. 2016;137(1):327–30.
Acknowledgements
We thank Prof Dr Eleonora Aronica and Dr Maurits van Montfoort for providing pathology biopsy specimens and their expertise regarding the interpretation and Prof Dr Ineke ten Berge for critically reading the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Electronic Supplementary Material
Supplementary table 1
(DOCX 25 kb)
Supplementary figure 1
FACS plots showing the expression of FOXP3 and CD25 (top panels), CD127 and CD25 (middle panels), and Helios and FOXP3 (bottom panels) on gated CD4+ T cells from controls (black) and the patient (in red) before and after treatment with abatacept. (PPTX 140 kb)
Rights and permissions
About this article
Cite this article
van Leeuwen, E.M., Cuadrado, E., Gerrits, A.M. et al. Treatment of Intracerebral Lesions with Abatacept in a CTLA4-Haploinsufficient Patient. J Clin Immunol 38, 464–467 (2018). https://doi.org/10.1007/s10875-018-0511-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-018-0511-1